We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The retrospective study included 951 patients with ...
Please provide your email address to receive an email when new articles are posted on . The study comprised 264,590 patients whose eosinophil levels were measured. There were no significant changes in ...
(NewsNation) — Whether it’s a change in appetite, new lumps or persisting fatigue, there are plenty of things patients can monitor as potential cancer indicators. One potential cancer indicator — a ...
Analysis of plasma-based BRAF and NRAS mutation detection in patients with stage III and IV melanoma. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This abstract does not ...
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC today announced positive top-line results in a Phase 2 dose-ranging trial of the novel oral drug dexpramipexole in patients with moderate-to-severe ...
Efficacy and safety of PD-1/PD-L1 inhibitor plus platinum-based chemotherapy vs. platinum-based chemotherapy alone in patients with previously untreated advanced large-cell neuroendocrine cancer of ...
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC today announced detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results